Clinical trials: CD
Crohn's Disease
A Study of the Efficacy and Safety of Risankizumab in Participants With Moderately to Severely Active Crohn's Disease
The purpose of this study is to evaluate the efficacy and safety of risankizumab versus placebo during induction therapy in participants with moderately to severely active Crohn's disease (CD).
- Trial name
- NCT03105128
- Testing
- risankizumab IV, risankizumab SC
- Where
- 475 sites in United States, Argentina and 42 more
- Volunteers
- 931 people
- Sponsor
- AbbVie
Crohn Disease
A Phase 2a Safety and Efficacy Open-Label Study of Tulisokibart (MK-7240/PRA023) in Participants With Moderately to Severely Active Crohn's Disease (MK-7240-006)
The purpose of this study is to assess the safety and efficacy of tulisokibart (MK-7240) in participants with moderately to severely active Crohn's Disease.
- Trial name
- APOLLO-CD (NCT05013905)
- Testing
- Tulisokibart, Companion Diagnostic (CDx)
- Where
- 37 sites in United States, Australia and 6 more
- Volunteers
- 55 people
- Sponsor
- Prometheus Biosciences, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Crohn's Disease
Efficacy and Safety Study of Ontamalimab as Induction Therapy in Participants With Moderate to Severe Crohn's Disease (CARMEN CD 306)
The purpose of this study is to evaluate the efficacy and safety of Ontamalimab in inducing clinical remission and endoscopic response in participants with moderate to severe Crohn's Disease.
- Trial name
- CARMEN CD 306 (NCT03566823)
- Testing
- Ontamalimab
- Where
- 145 sites in United States, Argentina and 18 more
- Volunteers
- 34 people
- Sponsor
- Shire
Psoriasis
Efficacy and Safety Study of CD 2027 Spray in Subjects With Plaque-type Psoriasis
This was a multicenter, randomized, vehicle-controlled, double-blind parallel group study to evaluate the efficacy and safety of CD 2027 Oily Spray applied twice daily for 8 weeks in participants with plaque-type psoriasis.
- Trial name
- NCT00763555
- Testing
- CD 2027, Calcitriol Vehicle
- Where
- 6 sites in United States, Canada
- Volunteers
- 88 people
- Sponsor
- Galderma R&D
Crohn Disease
A Study to Evaluate Safety of Long Term Therapy of Certolizumab Pegol Patients With Crohn's Disease
The primary objective of the study is to assess the safety of long term therapy with Certolizumab Pegol in those subjects participating in study C87085 [NCT00552058].
- Trial name
- NCT00552344
- Testing
- Cimzia
- Where
- 100 sites in United States, Australia and 16 more
- Volunteers
- 403 people
- Sponsor
- UCB BIOSCIENCES GmbH
Colitis, Ulcerative, Crohn Disease
A Study to Observe Vedolizumab and Anti-tumour Necrosis Factors (Anti-TNFs) Outcomes in Real-world Biologic Ulcerative Colitis (UC) and Crohn's Disease (CD) Participants
The purpose of this study is to describe treatment patterns associated with first-line and second line biologic use (vedolizumab or other biologic) and to describe the real-world clinical effectiveness of the use (first-line and…
- Trial name
- EVOLVE-IBERIA (NCT03710486)
- Where
- 26 sites in Portugal, Spain
- Volunteers
- 409 people
- Sponsor
- Takeda
Ulcerative Colitis, Crohn's Disease
Long-term Safety With Vedolizumab Intravenous (IV) in Pediatric Participants With Ulcerative Colitis (UC) or Crohn's Disease (CD)
The purpose of this study is to determine the safety profile of long-term vedolizumab IV treatment in pediatric participants with UC or CD.
- Trial name
- NCT03196427
- Testing
- Vedolizumab
- Where
- 23 sites in United States, France and 5 more
- Volunteers
- 59 people
- Sponsor
- Takeda
Rheumatoid Arthritis, Psoriatic Arthritis
A Study in Pregnant Women With Chronic Inflammatory Diseases Treated With Cimzia (Certolizumab Pegol)
The purpose of the study is to assess systemic certolizumab pegol (CZP) exposure, the formation of anti-CZP antibodies and safety of CZP across the course of pregnancy in study participants with chronic inflammatory diseases.
- Conditions
- Rheumatoid Arthritis, Psoriatic Arthritis, Crohn's Disease, Axial Spondyloarthritis
- Trial name
- CHERISH (NCT04163016)
- Testing
- Pharmacokinetics of certolizumab pegol
- Where
- 9 sites in United States, France and 4 more
- Volunteers
- 22 people
- Sponsor
- UCB Biopharma SRL
Crohn's Disease
Intra-erythrocyte Dexamethasone Versus Placebo in Patients With Steroid-dependent Crohn's Disease
Primary objective: Assessment of the efficacy of EryDex vs PLACEBO in maintaining patients with steroid-dependent Crohn's disease in clinical remission throughout 12 months without oral steroids. Secondary objectives: 1.
- Trial name
- Crodex (NCT01277289)
- Testing
- Dexamethasone
- Where
- 8 sites in Italy, Romania and 1 more
- Volunteers
- 51 people
- Sponsor
- Quince Therapeutics S.p.A.
Crohn's Disease
Efficacy and Safety Study of Ontamalimab as Maintenance Treatment in Participants With Moderate to Severe Crohn's Disease (CARMEN CD 307)
The purpose of this study is to evaluate the efficacy and safety of ontamalimab as maintenance treatment in participants with moderate to severe Crohn's disease (CD).
- Trial name
- CARMEN CD 307 (NCT03627091)
- Testing
- Ontamalimab
- Where
- 281 sites in United States, Argentina and 32 more
- Volunteers
- 40 people
- Sponsor
- Shire
Recurrent Clostridium Difficile Infection
Microbiota Restoration Therapy for Recurrent Clostridium Difficile-associated Diarrhea
This study will assess the safety of a new biologic drug, RBX2660 (microbiota suspension) as a treatment for recurrent Clostridium difficile-associated diarrhea (CDAD), which is the primary symptom of recurrent Clostridium…
- Trial name
- PUNCH CD (NCT01925417)
- Testing
- RBX2660 (microbiota suspension)
- Where
- 13 sites in United States
- Volunteers
- 34 people
- Sponsor
- Rebiotix Inc.
Crohn's Disease
A follow-on Safety Study of CDP870 in Subjects With Crohn's Disease (CD) Who Have Completed a 26-week Double Blind Study CDP870-031 [NCT00152490] or CDP870-032 [NCT00152425]
An open-label follow-on safety study of CDP870 (400 mg every 4 weeks) in patients with Crohn's Disease who have completed a 26-week blinded study (CDP870-031 [NCT00152490] or CDP870-032 [NCT00152425]).
- Trial name
- PRECiSE 3 (NCT00160524)
- Testing
- Certolizumab Pegol (CDP870)
- Where
- 206 sites in United States, Australia and 27 more
- Volunteers
- 596 people
- Sponsor
- UCB Pharma SA
Crohn's Disease (CD)
A Study to Evaluate the Long-Term Efficacy, Safety, and Tolerability of Repeated Administration of Upadacitinib (ABT-494) in Participants With Crohn's Disease
This is a open-label extension (OLE) study designed to evaluate the long-term efficacy, safety, and tolerability of Upadacitinib (ABT-494).
- Trial name
- NCT02782663
- Testing
- ABT-494
- Where
- 61 sites in United States, Belgium and 16 more
- Volunteers
- 107 people
- Sponsor
- AbbVie
Crohn Disease
Triple Combination Therapy in High Risk Crohn's Disease (CD)
The purpose of this study is to determine the effect of triple combination therapy with an anti-integrin (vedolizumab intravenous [IV]), a tumor necrosis factor (TNF) antagonist (adalimumab subcutaneously [SC]), and an…
- Trial name
- NCT02764762
- Testing
- Vedolizumab, Adalimumab, Methotrexate
- Where
- 32 sites in United States, Canada
- Volunteers
- 55 people
- Sponsor
- Takeda
Degenerative Spinal Disease, Deformity of Spine
Fenestrated Screw Study
The primary objective of this post-market study is to demonstrate that Oswestry disability index (ODI) score improved significantly at 12 months post-operatively as compared to baseline for each indication (degenerative spinal…
- Trial name
- FNS (NCT03797144)
- Testing
- CD HORIZON® Fenestrated Screw System with Fenestrated Screw Cement
- Where
- 6 sites in Belgium, Finland and 3 more
- Volunteers
- 27 people
- Sponsor
- Medtronic Spinal and Biologics
Pediatric Crohn's Disease
Post-Marketing Surveillance of Humira in Korean Pediatric Crohn's Disease (CD) Patients Under the "New-Drug Re-examination"
This study is a non-interventional, observational study of Humira® in the treatment of pediatric CD as per the New Drug Re-examination Guideline in Korea.
- Trial name
- NCT02578238
- Volunteers
- 143 people
- Sponsor
- AbbVie
Crohn Disease
Clinical Study Comparing PillCam® Crohn's Capsule Endoscopy to Ileocolonoscopy (IC) Plus MRE for Detection of Active CD in the Small Bowel and Colon in Subjects With Known CD and Mucosal Disease.
This study will evaluate the efficacy of capsule endoscopy (CE) versus ileocolonoscopy (IC) plus MRE for detection of active Crohn's disease (CD) in the small bowel in subjects with known CD and mucosal disease.
- Trial name
- BLINK (NCT03241368)
- Testing
- Capsule Endoscopy
- Where
- 26 sites in United States, Austria and 1 more
- Volunteers
- 187 people
- Sponsor
- Medtronic - MITG
Known Crohn Disease Subjects
Monitoring Disease Activity Using Video Capsule Endoscopy (VCE) in Crohn's Disease (CD) Subjects
This study is designed to evaluate the performance of VCE in the assessment of mucosal inflammation 6 months after the first VCE procedure
- Trial name
- NCT01942720
- Testing
- Capsule endoscopy and Ileocolonoscopy tests
- Where
- 15 sites in United States
- Volunteers
- 74 people
- Sponsor
- Medtronic - MITG
Herpes Zoster
A Study to Evaluate the Safety and Immunogenicity of Inactivated Varicella-Zoster Virus (VZV) Vaccine in Adults With Hematologic Malignancies (HM) Receiving Treatment With Anti-Cluster of Differentiation (CD) 20 Monoclonal Antibodies (V212-013)
An open-label, multicenter study to evaluate the safety and immunogenicity of inactivated VZV vaccine (V212) in participants with hematologic malignancies (HM) who are currently receiving anti-CD20 monoclonal antibodies.
- Trial name
- NCT01460719
- Testing
- V212
- Volunteers
- 80 people
- Sponsor
- Merck Sharp & Dohme LLC
Crohn's Disease
A Long-Term Registry of Humira® (Adalimumab) in Subjects With Moderately to Severely Active Crohn's Disease (CD)
The purpose of this Registry study is to evaluate the long-term safety and effectiveness of adalimumab in CD subjects who are treated as recommended in the product label.
- Trial name
- NCT00524537
- Volunteers
- 5,025 people
- Sponsor
- AbbVie (prior sponsor, Abbott)